Comparative Pharmacology
Head-to-head clinical analysis: AN DTPA versus PHOSPHOTOPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AN DTPA versus PHOSPHOTOPE.
AN-DTPA vs PHOSPHOTOPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AN-DTPA (pentetate calcium trisodium) is a chelating agent that binds to and removes heavy metals, such as plutonium, americium, curium, and other transuranic elements, from the body. It forms stable complexes with these metals, which are then excreted via the kidneys.
Unknown; proposed to normalize phosphate metabolism and inhibit ectopic calcification by binding to calcium and phosphate.
1 gram by intravenous injection or infusion daily for 5 consecutive days, starting immediately after the end of radiotherapy.
10-20 mcg/kg intravenous bolus over 1-2 minutes, may repeat every 10-20 minutes as needed for hemodynamic support. Maximum total dose: 1 mg.
None Documented
None Documented
Terminal elimination half-life: approximately 1.5-2 hours in patients with normal renal function. Extended significantly in renal impairment (up to 24 hours in anuria).
Terminal elimination half-life: 4-6 hours in patients with normal renal function; prolonged to 12-24 hours in moderate renal impairment (CrCl <30 mL/min) and >24 hours in dialysis-dependent patients.
Renal: >95% as unchanged drug via glomerular filtration. Biliary/fecal: <5%.
Renal: 70-80% as unchanged drug; fecal: 15-20% as metabolites; biliary: <5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical